. ▁ ▁Ne uro prote ction ▁ ▁Ne uro prote ct ive ▁dru gs ▁aim ▁at ▁en abling ▁the ▁surv ival ▁of ▁motor ▁neur ons ▁even ▁with ▁low ▁levels ▁of ▁SM N ▁protein . ▁▁ ▁O les ox ime ▁is ▁a ▁propriet ary ▁ne uro prote ct ive ▁comp ound ▁developed ▁by ▁the ▁French ▁company ▁Tro ph os , ▁later ▁acquired ▁by ▁Hoff mann - La ▁Ro che , ▁which ▁showed ▁stabil ising ▁effect ▁in ▁a ▁phase - II ▁clin ical ▁trial ▁involving ▁people ▁with ▁S MA ▁types ▁ 2 ▁and ▁ 3 . ▁Its ▁development ▁was ▁dis cont in ued ▁in ▁ 2 0 1 8 ▁in ▁view ▁of ▁competition ▁with ▁Sp in ra za ▁and ▁worse ▁than ▁expected ▁data ▁coming ▁from ▁an ▁open - label ▁extension ▁trial . ▁ ▁Of ▁clin ically ▁studied ▁comp ounds ▁which ▁did ▁not ▁show ▁effic acy , ▁thy rot rop in - re le asing ▁h orm one ▁( TR H ) ▁held ▁some ▁promise ▁in ▁an ▁open - label ▁un control led ▁clin ical ▁trial ▁but ▁did ▁not ▁prove ▁effective ▁in ▁a ▁subsequent ▁double - bl ind ▁place bo - control led ▁trial . ▁R il uz ole , ▁a ▁drug ▁that ▁has ▁m ild ▁clin ical ▁benefit ▁in ▁am y ot roph ic ▁later al ▁s cl eros is , ▁was ▁proposed ▁to ▁be ▁similarly ▁tested ▁in ▁S MA , ▁however ▁a ▁ 2 0 0 8 – 2 0 1 0 ▁trial ▁in ▁S MA ▁types ▁ 2 ▁and ▁ 3 ▁was ▁stopped